Search Results - "Tama, Elif"

S1651 Association of Leptin-Melanocortin Pathway Genetic Variants and Obesity-Related Phenotypic Traits by Fansa, Sima, Ghusn, Wissam, Anazco, Diego, Tama, Elif, Hurtado, Maria Daniela, Acosta, Andres

Get full text

S2120 Tirzepatide and MASLD: Real-World Outcomes in Patients With Overweight and Obesity by Espinosa, Maria A, Fansa, Sima, Anazco, Diego, Ghusn, Wissam, Elif, Tama, Cifuentes, Lizeth, Alejandro, Campos, Rivera, Rene, Hurtado, Maria D, Acosta, Andres

Get full text

S1666 Association of Resting Energy Expenditure and Satiation Parameters in Patients With Obesity by Anazco, Diego, Calderon, Gerardo, Ghusn, Wissam, Cifuentes, Lizeth, Fansa, Sima, Tama, Elif, Gala, Khushboo, Hurtado, Maria Daniela, Acosta, Andres

“…Food intake is a tightly regulated process with 3 distinct stages: hunger, satiation, and postprandial satiety. All patients underwent a set of behavioral and…”
Get full text

S1648 Cardiovascular Disease Risk Improvement With Semaglutide in Patients With Obesity: A Multi-Centered Study by Ghusn, Wissam, Anazco, Diego, Fansa, Sima, Tama, Elif, De La Rosa, Alan, Nicolalde, Bryan, Cifuentes, Lizeth, Sacoto, Daniel, Campos, Alejandro, Feris, Fauzi, Gala, Khushboo, Calderon, Gerardo, Hashem, Anas, Hurtado, Maria Daniela, Acosta, Andres

“…[...]there is a significant need to prevent CVD by targeting excess adiposity in patients with obesity. Secondary outcomes included total body weight loss…”
Get full text

S1485 Semaglutide Outcomes in Non-Alcoholic Fatty Liver Disease: A Multi-Centered Real-World Study by Ghusn, Wissam, Fansa, Sima, Anazco, Diego, Tama, Elif, Nicolalde, Bryan, Gala, Khushboo, Cifuentes, Lizeth, De La Rosa, Alan, Sacoto, Daniel, Campos, Alejandro, Feris, Fauzi, Acosta, Andres

Get full text

Efficacy of in-person versus digital enhanced lifestyle interventions in adults with overweight and obesity by Anazco, Diego, Espinosa, Maria A., Cifuentes, Lizeth, Kassmeyer, Blake, Schmidt, Tara M., Fansa, Sima, Campos, Alejandro, Tama, Elif, Harmsen, William S., Hurtado, Maria D., Hensrud, Donald D., Acosta, Andres

“…Lifestyle interventions (LIs) are the cornerstone for obesity management. The Mayo Clinic Diet (MCD) offers two approaches for LIs: the In-Person LI (IPLI) and…”
Get full text

1707-P: Real-World 12-Month Weight Loss Outcomes of Tirzepatide-The Mayo Clinic Experience by Fansa, Sima, Tama, Elif, Safwan, Nancy, Ghusn, Wissam, Anazco, Diego, Acosta, Andres, Hurtado, Maria D

“…Introduction: Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been recently approved for the treatment of overweight and obesity given its proven…”
Get full text

Cumulative effect of obesity phenotypes on body weight and body mass index by Ghusn, Wissam, Cifuentes, Lizeth, Anazco, Diego, Fansa, Sima, Tama, Elif, Campos, Alejandro, Gala, Khushboo, Hurtado, Daniela Maria, Acosta, Andres

“…Background Obesity originates from an imbalance between energy intake and expenditure. Changes in energy intake components (satiation, postprandial satiety,…”
Get full text

234-OR: Performance of a Machine-Learning Gene Risk Score Biomarker to Predict Weight-Loss Response to Tirzepatide and Semaglutide by Tama, Elif, Fansa, Sima, Anazco, Diego, Rivera, Rene, Ghusn, Wissam, Cifuentes, Lizeth, Acosta, Andres, Hurtado, Maria D

“…Introduction: Abnormal post-prandial satiety obesity phenotype (APS+) is characterized by rapid gastric emptying. The GLP-1 analog liraglutide delays gastric…”
Get full text

Performance Characteristics of Polygenic Risk Score for Satiation in Food Intake Regulation by Fansa, Sima, Cifuentes, Lizeth, Campos, Alejandro, Ghusn, Wissam, McRae, Alison, Anazco, Diego, Tama, Elif, Hurtado, Maria Daniela, Acosta, Andres

“…Background: Satiation, defined as the calories consumed to reach fullness, is a key component of food intake regulation. Satiation is measured by number of…”
Get full text

Weight Loss Response to Semaglutide in Menopausal Women with and without Menopausal Hormone Therapy by Tama, Elif, Ghusn, Wissam, Fansa, Sima, Anazco, Diego, Faubion, Stephanie, Shufelt, Chrisandra, Acosta, Andres, Hurtado, Maria Daniela

Get full text

The relation between excess adiposity and breast cancer in women: Clinical implications and management by Hurtado, Maria D., Tama, Elif, D’Andre, Stacey, Shufelt, Chrisandra L.

“…Breast cancer (BC) is the most common cancer in women. While the combination of improved screening, earlier detection, and advances in therapeutics has…”
Get full text

1660-P: Efficacy and Safety of Tirzepatide for the Treatment of Obesity in Adults with Type 1 Diabetes—The Mayo Clinic Experience by TAMA, ELIF, BECHENATI, DIMA, BENNETT, PAMELA, MCNALLY, ALLYSON, RIVERA, RENE, FANSA, SIMA, ANAZCO, DIEGO, ACOSTA, ANDRES, HURTADO, MARIA D.

“…Introduction: The efficacy and safety of tirzepatide for the treatment of overweight/obesity are well established in adults with type 2, but not type 1,…”
Get full text

1283 SATIATION TESTING AND A SURROGATE MACHINE-LEARNING ASSISTED GENE RISK SCORE BIOMARKER PREDICT DIFFERENTIAL RESPONSES TO LIFESTYLE INTERVENTIONS: A POST-HOC ANALYSIS OF A SINGLE CENTER, NON-RANDOMIZED CLINICAL TRIAL by Anazco, Diego, Cifuentes, Lizeth, Fansa, Sima, Ghusn, Wissam, Campos, Alejandro, Tama, Elif, Gala, Khushboo, Stutzman, Jessica, Schaefer, Megan, Hensrud, Donald, Hurtado, Maria D., Acosta, Andres

Get full text

Sa1951 CLINICAL PARAMETERS ASSOCIATED WITH SEMAGLUTIDE INTOLERANCE IN PATIENTS WITH DIABETES AND OBESITY by Ghusn, Wissam, Anazco, Diego, Fansa, Sima, Tama, Elif, Cifuentes, Lizeth, Campos, Alejandro, Gala, Khushboo, Calderon, Gerardo, Hurtado, Maria D., Acosta, Andres

Get full text

638 PERFORMANCE OF A MACHINE-LEARNING GENE RISK SCORE BIOMARKER ON PREDICTING RESPONSE TO SEMAGLUTIDE: A PROSPECTIVELY FOLLOWED MULTI-CENTER BIOBANK AND OUTCOMES REGISTRY by Fansa, Sima, Tama, Elif, Anazco, Diego, Cifuentes, Lizeth, Ghusn, Wissam, Gala, Khushboo, Kolkin, Elle, O'Connor, Timothy R., Acosta, Andres, Hurtado, Maria D.

Get full text

Weight Loss Response to Semaglutide in Post-menopausal Women with and without Hormone Therapy Use by Hurtado, Maria D., Tama, Elif, Fansa, Sima, Ghusn, Wissam, Anazco, Diego, Acosta, Andres, Faubion, Stephanie S., Shufelt, Chrisandra L.

Get full text

Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks by Thota-Kammili, Sanjana, Tama, Elif, Hurtado Andrade, Maria D.

“…Purpose of Review The glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) liraglutide and semaglutide, and the dual GLP-1/glucose-dependent insulinotropic…”
Get full text

The association between previous use of anti‐obesity medication and semaglutide weight loss outcomes by Ghusn, Wissam, Fansa, Sima, Anazco, Diego, Tama, Elif, Cifuentes, Lizeth, Gala, Khushboo, De La Rosa, Alan, Sacoto, Daniel, Campos, Alejandro, Feris, Fauzi, Hurtado, Daniela, Acosta, Andres

“…Aims To compare weight loss outcomes between patients starting semaglutide who had previously been on another anti‐obesity medication (AOM) compared to those…”
Get full text

Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study by Ghusn, Wissam, Fansa, Sima, Anazco, Diego, Tama, Elif, Nicolalde, Bryan, Gala, Khushboo, De la Rosa, Alan, Sacoto, Daniel, Cifuentes, Lizeth, Campos, Alejandro, Feres, Fauzi, Hurtado, Maria Daniela, Acosta, Andres

“…Background/Objective There are limited real-world studies assessing semaglutide weight loss and associated comorbidity and metabolic outcomes over periods ≥ 6…”
Get full text